Immune-checkpoint blockade of CTLA-4 (CD152) in antigen-specific human T-cell responses differs profoundly between neonates, children, and adults

The monoclonal antibody against CTLA-4, Ipilimumab, is a first-in-class immune-checkpoint inhibitor approved for treatment of advanced melanoma in adults but not extensively studied in children. In light of the fact that the immune response early in life differs from that of adults, we have applied...

Descripció completa

Dades bibliogràfiques

Autors principals:	Aditya Arra, Maximilian Pech, Hang Fu, Holger Lingel, Franziska Braun, Christian Beyer, Myra Spiliopoulou, Barbara M. Bröker, Karen Lampe, Christoph Arens, Katrin Vogel, Mandy Pierau, Monika C. Brunner-Weinzierl
Format:	Artigo
Idioma:	Inglês
Publicat:	Taylor & Francis Group 2021-01-01
Col·lecció:	OncoImmunology
Matèries:	ctla-4 adults neonates children cd40l multifunctional t-cells s. aureus
Accés en línia:	http://dx.doi.org/10.1080/2162402X.2021.1938475
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!